Amygdala Neurosciences Overview

  • Year Founded
  • 2015

Year Founded

  • Status
  • Private

  • Employees
  • 3

Employees

  • Latest Deal Type
  • Grant

  • Latest Deal Amount
  • $2M

  • Investors
  • 4

Amygdala Neurosciences General Information

Description

Developer of a biopharmaceutical technology intended to focus on the large and growing unmet need associated with substance use disorders. The company's technology uses a selective ALDH2 inhibitor that prevents a surge in dopamine levels and associated cravings without changes to basal dopamine, enabling patients to quit and get rid of their addiction to drugs, alcohol, and smoking.

Contact Information

Website
www.amygns.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 5214F Diamond Heights Boulevard
  • Suite 151
  • San Francisco, CA 94131
  • United States
+1 (650)
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Vertical(s)
Corporate Office
  • 5214F Diamond Heights Boulevard
  • Suite 151
  • San Francisco, CA 94131
  • United States
+1 (650)

Amygdala Neurosciences Timeline

2022202320242025
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Amygdala Neurosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Grant 01-Aug-2023 $2M Completed Pre-Clinical Trials
7. Grant 10-Sep-2021 Completed Pre-Clinical Trials
6. Seed Round 28-Apr-2021 Completed Pre-Clinical Trials
5. Grant 21-Oct-2019 Completed Pre-Clinical Trials
4. Grant 19-Sep-2018 Completed Pre-Clinical Trials
3. Seed Round 19-May-2017 Completed Pre-Clinical Trials
2. Seed Round 10-Feb-2017 $2M $3.45M Completed Pre-Clinical Trials
1. Seed Round 10-Apr-2015 $1.45M $1.45M Completed Pre-Clinical Trials
To view Amygdala Neurosciences’s complete valuation and funding history, request access »

Amygdala Neurosciences Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate ($) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Seed-4
Seed-3
Seed-2 4,340,673 $0.000100 $0.03 $0.55 $0.55 1x $0.5 11.97%
Seed-1 5,307,464 $0.000100 $0.02 $0.27 $0.27 1x $0.27 13.24%
To view Amygdala Neurosciences’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Amygdala Neurosciences Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a biopharmaceutical technology intended to focus on the large and growing unmet need associated with substa
Drug Discovery
San Francisco, CA
3 As of 2025

Cambridge, MA
 

San Carlos, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Amygdala Neurosciences Competitors (54)

One of Amygdala Neurosciences’s 54 competitors is Mitobridge, a Formerly VC-backed company based in Cambridge, MA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Mitobridge Formerly VC-backed Cambridge, MA
Alkahest Formerly VC-backed San Carlos, CA
Astrocyte Pharma Venture Capital-Backed Groton, CT
Aro Biotherapeutics Venture Capital-Backed Philadelphia, PA
Alzheon Venture Capital-Backed Framingham, MA
You’re viewing 5 of 54 competitors. Get the full list »

Amygdala Neurosciences Patents

Amygdala Neurosciences Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
AU-2023292243-A1 Aldh-2 inhibitor compounds and methods of use Pending 14-Jun-2022
AU-2023295214-A1 Aldh-2 inhibitor compounds and methods of use Pending 14-Jun-2022
EP-4540228-A1 Aldh-2 inhibitor compounds and methods of use Pending 14-Jun-2022
EP-4540237-A1 Aldh-2 inhibitor compounds and methods of use Pending 14-Jun-2022
US-12018009-B2 Aldh-2 inhibitor compounds and methods of use Active 14-Jun-2022 C07D401/04
To view Amygdala Neurosciences’s complete patent history, request access »

Amygdala Neurosciences Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Amygdala Neurosciences Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds
National Institutes of Health Government
Altamont Pharmaceutical Holdings Holding Company Minority
Asset Management Ventures Venture Capital Minority
National Institute of Alcohol Abuse and Alcoholism Government
To view Amygdala Neurosciences’s complete investors history, request access »

Amygdala Neurosciences Investments (1)

Amygdala Neurosciences’s most recent deal was a Corporate Asset Purchase with Gilead Sciences (GS-6637). The deal was made on 16-Feb-2017.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Gilead Sciences (GS-6637) 16-Feb-2017 Corporate Asset Purchase Buildings and Property
To view Amygdala Neurosciences’s complete investments history, request access »

Amygdala Neurosciences FAQs

  • When was Amygdala Neurosciences founded?

    Amygdala Neurosciences was founded in 2015.

  • Where is Amygdala Neurosciences headquartered?

    Amygdala Neurosciences is headquartered in San Francisco, CA.

  • What is the size of Amygdala Neurosciences?

    Amygdala Neurosciences has 3 total employees.

  • What industry is Amygdala Neurosciences in?

    Amygdala Neurosciences’s primary industry is Drug Discovery.

  • Is Amygdala Neurosciences a private or public company?

    Amygdala Neurosciences is a Private company.

  • What is Amygdala Neurosciences’s current revenue?

    The current revenue for Amygdala Neurosciences is .

  • How much funding has Amygdala Neurosciences raised over time?

    Amygdala Neurosciences has raised $10.1M.

  • Who are Amygdala Neurosciences’s investors?

    National Institutes of Health, Altamont Pharmaceutical Holdings, Asset Management Ventures, and National Institute of Alcohol Abuse and Alcoholism have invested in Amygdala Neurosciences.

  • Who are Amygdala Neurosciences’s competitors?

    Mitobridge, Alkahest, Astrocyte Pharma, Aro Biotherapeutics, and Alzheon are some of the 54 competitors of Amygdala Neurosciences.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »